← Leaderboards
John M. Wrangle
Medical University Of South Carolina
$2,019,783
Attributed
$3,651,307
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,651,307 · 3
By mechanism
R01$1,969,523 · 1
K12$1,293,525 · 1
R21$388,259 · 1
Top collaborators
- Mark P Rubinstein5 shared
- Albert Craig Lockhart2 shared
- David M. Neskey1 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Mark P Rubinstein$2,818,767
- Philip H Howe$17,002,249
- Besim Ogretmen$19,638,711
- Sophie Paczesny$15,189,813
- Dennis K Watson$3,433,120
Others in their field
Other Emerging Leaders on “Clinic”
- Leonard Freedman · Leidos Biomedical Research, Inc.$978,089,882
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$321,499,704
- Lynn Briscoe · Leidos Biomedical Research, Inc.$317,501,839
Research focus
ClinicMalignant NeoplasmsResearch PersonnelFundingOncologyMalignant Neoplasm Of LungMouse ModelProductionTumorToxic EffectMediatingImmunotherapyInvestigationMelanomaApplications GrantsAnti-Tumor Immune ResponseComplexChemokineCheckpoint TherapyClinical TrialsCritical PathwaysCaringAntibodiesCd8b1 Gene
Grant awards (10)
Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ$176,481
R21 · FY2025 · CA · contact PI
Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ$211,778
R21 · FY2024 · CA · contact PI
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses$389,857
R01 · FY2023 · CA · contact PI
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$396,181
K12 · FY2022 · CA · contact PI
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses$389,857
R01 · FY2022 · CA · contact PI
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$616,373
K12 · FY2021 · CA · contact PI
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses$397,814
R01 · FY2021 · CA · contact PI
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses$397,814
R01 · FY2020 · CA
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$280,971
K12 · FY2020 · CA · contact PI
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses$394,181
R01 · FY2019 · CA